keyword
MENU ▼
Read by QxMD icon Read
search

Gardasil

keyword
https://www.readbyqxmd.com/read/28720462/a-novel-trivalent-hpv-16-18-58-vaccine-with-anti-hpv-16-and-18-neutralizing-antibody-responses-comparable-to-those-induced-by-the-gardasil-quadrivalent-vaccine-in-rhesus-macaque-model
#1
Fei Yin, Yajun Wang, Na Chen, Dunquan Jiang, Yefeng Qiu, Yan Wang, Mei Yan, Jianping Chen, Haijiang Zhang, Yongjiang Liu
Persistent infection with human papillomavirus (HPV) is a key factor in the development of precancerous lesions and invasive cervical cancer. Prophylactic vaccines to immunize against HPV are an effective approach to reducing HPV related disease burden. In this study, we investigated the immunogenicity and dosage effect of a trivalent HPV 16/18/58 vaccine (3vHPV) produced in Escherichia coli (E.coli), with Gardasil quadrivalent vaccine (4vHPV, Merck & Co.) as a positive control. Sera collected from rhesus macaques vaccinated with three dosage formulations of 3vHPV (termed low-, mid-, and high-dosage formulations, respectively), and the 4vHPV vaccine were analyzed by both Pseudovirus-Based Neutralization Assay (PBNA) and Enzyme-Linked Immunosorbent Assay (ELISA)...
June 2017: Papillomavirus Research
https://www.readbyqxmd.com/read/28710539/-treatment-outcomes-of-recurrent-respiratory-papillomatosis-retrospective-analysis-of-juvenile-and-adult-cases-german-version
#2
V-A Papaioannou, A Lux, S Voigt-Zimmermann, C Arens
BACKGROUND: Recurrent respiratory papillomatosis (RRP) is a rare, chronic disease of viral etiology which is characterized by multiple, recurrent growth of papillomas in the aerodigestive tract. MATERIALS AND METHODS: The surgical outcomes and the recurrence rates of 106 patients with RRP of the larynx were analyzed. The patients were treated at the University of Magdeburg between 1983 and 2014. The surgical outcomes of conventional and laser surgery regarding time to relapse and complications were compared...
July 14, 2017: HNO
https://www.readbyqxmd.com/read/28701899/cost-effectiveness-analysis-of-the-nine-valent-hpv-vaccine-in-italy
#3
Francesco Saverio Mennini, Paolo Bonanni, Florence Bianic, Chiara de Waure, Gianluca Baio, Giacomo Plazzotta, Mathieu Uhart, Alessandro Rinaldi, Nathalie Largeron
BACKGROUND: In Italy HPV vaccination with the quadrivalent vaccine (Gardasil(®)) is offered actively and free of charge to girls aged 12 since 2007. A nine-valent vaccine (Gardasil 9(®)) received the European market authorization in 2015 to protect, with only 2 doses, against around 90% of all HPV positive cancers, over 80% of high-grade precancerous lesions and 90% of genital warts caused by HPV types 6/11. METHODS: A dynamic transmission model simulating the natural history of HPV-infections was calibrated to the Italian setting and used to estimate costs and QALYs associated with vaccination strategies...
2017: Cost Effectiveness and Resource Allocation: C/E
https://www.readbyqxmd.com/read/28699820/expanded-strain-coverage-for-a-highly-successful-public-health-tool-prophylactic-9-valent-human-papillomavirus-vaccine
#4
Zhigang Zhang, Jun Zhang, Ningshao Xia, Qinjian Zhao
Human papillomavirus is considered the causative factor for cervical cancer, which accounts for approximately 5% of the global cancer burden and more than 600,000 new cases annually that are attributable to HPV infection worldwide. The first-generation prophylactic HPV vaccines, Gardasil® and Cervarix®, were licensed approximately a decade ago. Both vaccines contain the most prevalent high-risk types, HPV16 and 18, which are associated with 70% of cervical cancer. To further increase the type coverage, five additional oncogenic HPV types (31, 33, 45, 52 and 58) were added to the existing Gardasil-4 to develop a 9-valent HPV vaccine (9vHPV), Gardasil 9®, increasing the potential level of protection from ∼70% to ∼90%...
July 12, 2017: Human Vaccines & Immunotherapeutics
https://www.readbyqxmd.com/read/28656100/efficacy-of-human-papillomavirus-l1-protein-vaccines-cervarix-and-gardasil-in-reducing-the-risk-of-cervical-intraepithelial-neoplasia-a-meta-analysis
#5
REVIEW
Mohammad Reza Haghshenas, Tahoora Mousavi, Motahareh Kheradmand, Mahdi Afshari, Mahmood Moosazadeh
Human papillomavirus (HPV) can induce cervical intraepithelial neoplasia (CIN). Vaccination against HPV can play an important role in CIN prevention. This study aims to estimate the efficacy of L1 protein vaccines (Cervarix and Gardasil) in CIN 1, 2, 3 risk reduction using meta-analysis. Relevant articles were identified by two independent researchers searching international databanks. After application of inclusion/exclusion criteria and quality assessment, eligible articles were entered into the final meta-analysis...
2017: International Journal of Preventive Medicine
https://www.readbyqxmd.com/read/28641049/a-study-of-physicians-experiences-with-recommending-hpv-vaccines-to-adolescent-boys
#6
Li Ping Wong, Zobaida Edib, Haridah Alias, Sharina M Mohamad Shakir, Raja N A Raja Muhammad Yusoff, I-Ching Sam, Gregory D Zimet
Assessing physicians' experiences in HPV vaccine recommendation and delivery to adolescent boys is essential to providing an understanding of the issues of vaccine acceptance and an insight for policymakers to enhance HPV vaccinations among adolescent boys. Between January and April 2014 a mail survey was conducted using physicians in Malaysia known to provide either one or both HPV vaccine (Gardasil and Cervarix) immunisation services. A total of 357 completed questionnaires were received (response rate 22...
June 22, 2017: Journal of Obstetrics and Gynaecology: the Journal of the Institute of Obstetrics and Gynaecology
https://www.readbyqxmd.com/read/28575074/lessons-learnt-from-human-papillomavirus-hpv-vaccination-in-45-low-and-middle-income-countries
#7
Katherine E Gallagher, Natasha Howard, Severin Kabakama, Sandra Mounier-Jack, Ulla K Griffiths, Marta Feletto, Helen E D Burchett, D Scott LaMontagne, Deborah Watson-Jones
OBJECTIVE: To synthesise lessons learnt and determinants of success from human papillomavirus (HPV) vaccine demonstration projects and national programmes in low- and middle-income countries (LAMICs). METHODS: Interviews were conducted with 56 key informants. A systematic literature review identified 2936 abstracts from five databases; after screening 61 full texts were included. Unpublished literature, including evaluation reports, was solicited from country representatives; 188 documents were received...
2017: PloS One
https://www.readbyqxmd.com/read/28506297/cervical-cancer-treatment-costs-and-cost-effectiveness-analysis-of-human-papillomavirus-vaccination-in-vietnam-a-prime-modeling-study
#8
Hoang Van Minh, Nguyen Thi Tuyet My, Mark Jit
BACKGROUND: Cervical cancer is currently the leading cause of cancer mortality among women in South Vietnam and the second leading cause of cancer mortality in North Vietnam. Human papillomavirus (HPV) vaccination has the potential to substantially decrease this burden. The World Health Organization (WHO) recommends that a cost-effectiveness analysis of HPV vaccination is conducted before nationwide introduction. METHODS: The Papillomavirus Rapid Interface for Modeling and Economics (PRIME) model was used to evaluate the cost-effectiveness of HPV vaccine introduction...
May 15, 2017: BMC Health Services Research
https://www.readbyqxmd.com/read/28503996/primary-immunization-of-human-papillomavirus-vaccine-in-the-pediatric-population-what-is-the-verdict-now
#9
REVIEW
Aubrey N Jones, Jenna W Bartlett, Rebecca A Bates, Tsz-Yin So
The safety and efficacy of a 2-dose series for the human papillomavirus vaccines rather than a 3-dose series in older children has not been well defined. This article reviews the literature summarizing the use of all 3 HPV vaccines (2vHPV, 4vHPV, 9vHPV) as a 2-dose series for females and 4vHPV and 9vHPV for males younger than 15 years. Six prospective trials evaluating immunogenicity of a 2-dose series of 2vHPV and/or 4vHPV, as well as an ongoing prospective clinical trial for 9vHPV, are discussed. The 2-dose series with Gardasil 9(®) in both males and females ages 9 to 14 years appears to be the most widely accepted recommendation...
June 2017: Clinical Pediatrics
https://www.readbyqxmd.com/read/28483196/bacterially-expressed-human-papillomavirus-type-6-and-11-bivalent-vaccine-characterization-antigenicity-and-immunogenicity
#10
Huirong Pan, Zhihai Li, Jin Wang, Shuo Song, Daning Wang, Minxi Wei, Ying Gu, Jun Zhang, Shaowei Li, Ningshao Xia
Human papillomavirus (HPV)-6 and HPV11 are the major etiological causes of condylomata acuminate. HPV neutralization by vaccine-elicited neutralizing antibodies can block viral infection and prevent subsequent disease. Currently, two commercially available HPV vaccines cover these two genotypes, expressed by Saccharomyces cerevisiae. Here we describe another HPV6/11 bivalent vaccine candidate derived from Escherichia coli. The soluble expression of N-terminally truncated L1 proteins was optimized to generate HPV6- and HPV11 L1-only virus-like particles (VLPs) as a scalable process...
May 31, 2017: Vaccine
https://www.readbyqxmd.com/read/28442134/hpv-vaccines-a-review-of-the-first-decade
#11
REVIEW
Diane M Harper, Leslie R DeMars
Pre-adolescent girls (9-15years) have the option of receiving a two dose HPV vaccine series at either a six month or one year interval to provide protection from HPV 16, the most prevalent type associated with cervical cancers, as well as several other less prevalent types. This series of vaccinations is highly likely to protect her from HPV infection until she enters the routine screening program, whether that be primary HPV testing or a combination of HPV testing and cytology. The two dose program has been recommended by the World Health Organization (WHO) since 2015...
July 2017: Gynecologic Oncology
https://www.readbyqxmd.com/read/28404357/the-safety-and-immunogenicity-of-quadrivalent-hpv-qhpv-vaccine-in-systemic-lupus-erythematosus
#12
J Patricia Dhar, Lynnette Essenmacher, Renee Dhar, Ardella Magee, Joel Ager, Robert J Sokol
OBJECTIVE: This study evaluated the safety and immunogenicity of qHPV vaccine in SLE. METHODS: Subjects: 34 women ages 19-50years (yrs.) with mild to moderate SLE & minimally active or inactive SLE received qHPV vaccine at the standard dosing schedule. EXCLUSION CRITERIA: active SLE disease (SELENA-SLEDAI>2), history of severe SLE disease, deep venous thrombosis, on >400mg/day of hydroxychloroquine, on >15mg/day of prednisone, or active infections...
May 9, 2017: Vaccine
https://www.readbyqxmd.com/read/28362244/hpv-vaccines-global-perspectives
#13
Gaurav Gupta, Reinhard Glueck, Pankaj R Patel
The discovery of HPV as the etiological factor for HPV-associated malignancies and disease has opened up several opportunities for prevention and therapy. Current commercially available HPV vaccines (Gardasil, Gardasil 9, and Cervarix) are prophylactic in nature and derived from adjuvanted L1-based virus-like particles of HPV. Globally, through several clinical trials, they were found to be very safe and efficacious. Certain limitations such as cost-effectiveness, low coverage against all HPV types and a 3-dose schedule make these vaccines difficult to use worldwide...
June 3, 2017: Human Vaccines & Immunotherapeutics
https://www.readbyqxmd.com/read/28319456/reactogenicity-of-cervarix-and-gardasil-human-papillomavirus-hpv-vaccines-in-a-randomized-single-blind-trial-in-healthy-uk-adolescent-females
#14
Tao Haskins-Coulter, Jo Southern, Nick Andrews, Elizabeth Miller
One hundred and ninety eight females aged 12-15 y were enrolled in an observer-blinded randomized trial to assess the immunogenicity and reactogenicity of the tetravalent HPV vaccine Gardasil® (group 2), in comparison to the bivalent HPV vaccine, Cervarix® (group 1), which was routinely offered in the national vaccination schedule at the time. Participants were blinded to treatment group until all 3 vaccinations had been given, while laboratory staff were masked during testing. For the majority of local and general reactions, recipients of both vaccines reported comparable frequencies...
June 3, 2017: Human Vaccines & Immunotherapeutics
https://www.readbyqxmd.com/read/28288041/lymph-node-activation-by-pet-ct-following-vaccination-with-licensed-vaccines-for-human-papillomaviruses
#15
RANDOMIZED CONTROLLED TRIAL
Emily E Coates, Pamela J Costner, Martha C Nason, Douglas M Herrin, Shielah Conant, Peter Herscovitch, Uzma N Sarwar, Lasonji Holman, Jillian Mitchell, Galina Yamshchikov, Richard A Koup, Barney S Graham, Corina M Millo, Julie E Ledgerwood
BACKGROUND: While PET using F-FDG is most commonly used for imaging malignant tumors, vaccination is known to cause transient inflammation of lymph nodes inducing positive findings on F-FDG PET scans. The pattern, magnitude, and duration of lymph node activation following vaccination have not been clearly defined. Furthermore, the addition of adjuvants to vaccines can further enhance the immune response. The presented study was designed to define lymph node activation following administration of the Food and Drug Administration-licensed human papillomavirus vaccines, Cervarix and Gardasil, which contain similar antigens with different adjuvants...
May 2017: Clinical Nuclear Medicine
https://www.readbyqxmd.com/read/28034886/sustained-antibody-responses-6-years-following-1-2-or-3-doses-of-quadrivalent-human-papillomavirus-hpv-vaccine-in-adolescent-fijian-girls-and-subsequent-responses-to-a-single-dose-of-bivalent-hpv-vaccine-a-prospective-cohort-study
#16
Zheng Quan Toh, Fiona M Russell, Rita Reyburn, James Fong, Evelyn Tuivaga, Tupou Ratu, Cattram D Nguyen, Rachel Devi, Mike Kama, Silivia Matanitobua, Sepehr N Tabrizi, Suzanne M Garland, Rohit Sinha, Ian Frazer, Lisi Tikoduadua, Joseph Kado, Eric Rafai, Edward K Mulholland, Paul V Licciardi
Background: The duration of antibody response following reduced human papillomavirus (HPV) vaccine doses has not been determined. We compared the antibody responses in girls previously vaccinated with zero, 1, 2, or 3 doses of quadrivalent HPV vaccine (4vHPV; Gardasil, Merck) 6 years previously. Methods: A prospective cohort study was undertaken in 200 Fijian girls 15-19 years of age. Approximately equal numbers of girls from 2 main ethnic groups (Fijians of Indian descent [FID] and Indigenous Fijians [iTaukei]) in Fiji were recruited for each dosage groups...
April 1, 2017: Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America
https://www.readbyqxmd.com/read/27996119/bevacizumab-chemotherapy-for-management-of-pulmonary-and-laryngotracheal-papillomatosis-in-a-child
#17
Karen B Zur, Elizabeth Fox
Recurrent laryngeal papillomatosis (RRP) can be a devastating condition for a child to endure, and pulmonary involvement may have terminal consequences. Adjuvant therapies have been trialed and reported over the years; however, these chemotherapy options have not been successful. Bevacizumab (Avastin, Genetech Inc., South San Francisco, CA) is a vascular endothelial factor (VEGF) inhibitor that has shown promise in the management of papillomatosis. Most research has focused on intralesional injections of this antiangiogenic drug...
July 2017: Laryngoscope
https://www.readbyqxmd.com/read/27863633/intersurgical-interval-increased-with-use-of-quadrivalent-human-papillomavirus-vaccine-gardasil-in-a-pediatric-patient-with-recurrent-respiratory-papillomatosis-a-case-report
#18
Maraya M Baumanis, Charles A Elmaraghy
This is a case of a 4 year old female with recalcitrant recurrent respiratory papillomatosis with decreasing intersurgical interval that had improvement in clinical course after administration of the quadrivalent HPV vaccine.
December 2016: International Journal of Pediatric Otorhinolaryngology
https://www.readbyqxmd.com/read/27803416/two-cases-of-acute-disseminated-encephalomyelitis-following-vaccination-against-human-papilloma-virus
#19
Kenji Sekiguchi, Naoko Yasui, Hisatomo Kowa, Fumio Kanda, Tatsushi Toda
We herein present two cases of acute disseminated encephalomyelitis (ADEM) following vaccination against human papilloma virus (HPV). Case 1 experienced diplopia and developed an unstable gait 14 days after a second vaccination of Cervarix. Brain magnetic resonance imaging (MRI) showed an isolated small, demyelinating lesion in the pontine tegmentum. Case 2 experienced a fever and limb dysesthesia 16 days after a second vaccination of Gardasil. Brain MRI revealed hyperintense lesion in the pons with slight edema on a T2-weighted image...
2016: Internal Medicine
https://www.readbyqxmd.com/read/27771183/manufacturing-costs-of-hpv-vaccines-for-developing-countries
#20
Chaevia Clendinen, Yapei Zhang, Rebecca N Warburton, Donald W Light
BACKGROUND: Nearly all of the 500,000 new cases of cervical cancer and 270,000 deaths occur in middle or lower income countries. Yet the two most prevalent HPV vaccines are unaffordable to most. Even prices to Gavi, the Vaccine Alliance, are unaffordable to graduating countries, once they lose Gavi subsidies. Merck and Glaxosmithkline (GSK) claim their prices to Gavi equal their manufacturing costs; but these costs remain undisclosed. We undertook this investigation to estimate those costs...
October 19, 2016: Vaccine
keyword
keyword
12698
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"